Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer.

Related Articles

Chemotherapy-related leukopenia as a biomarker predicting survival outcomes in locally advanced cervical cancer.

Eur J Obstet Gynecol Reprod Biol. 2017 Jan;208:41-45

Authors: Bogani G, Sabatucci I, Maltese G, Lecce F, Signorelli M, Martinelli F, Chiappa V, Indini A, Leone Roberti Maggiore U, Borghi C, Fucà G, Ditto A, Raspagliesi F, Lorusso D

Abstract
OBJECTIVE: To investigate the impact of hematologic toxicity and leukopenia in locally advanced cervical cancer patients undergoing neoadjuvant chemotherapy (NACT).
STUDY DESIGN: Data of consecutive patients undergoing platinum-based NACT followed by surgery were retrospectively searched in order to evaluate the impact of chemotherapy-related toxicity on survival outcomes. Toxicity was graded per the Common Terminology Criteria for Adverse Events (CTCAEv.4.03). Survival outcomes were evaluated using Kaplan-Meir and Cox hazard models.
RESULTS: Overall, 126 patients were included. Among those, 94 (74.6%) patients experienced grade2+ hematologic toxicity; while, grade2+ non-hematologic toxicity occurred in 11 (8.7%) patients. After a median follow-up of 37.1 (inter-quartile range, 12-57.5) months, 21 (16.6%) patients experienced recurrence. Via multivariate analysis, no factor was independently associated with disease-free survival; while a trend toward worse prognosis was observed for patients experiencing grade2+ leukopenia at cycle-3 (HR:3.13 (95%CI: 0.94, 10.3); p=0.06). Similarly, grade2+ leukopenia (HR:9.98 (95%CI: 1.14, 86.6); p=0.03), lymph-node positivity (HR:14.6 (95%CI:1.0, 214.4); p=0.05) and vaginal involvement (HR:5.81 (95%CI:1.43, 23.6); p=0.01) impacted on overall survival, at multivariate analysis. Magnitude of leukopenia correlated with survival (p<0.001).
CONCLUSIONS: Although, our data have to be confirmed by prospective investigations, the present study shows an association between the occurrence of leukopenia and survival outcomes. NACT-related immunosuppression might reduce the response against the tumor, thus promoting cancer progression.

PMID: 27888705 [PubMed - indexed for MEDLINE]

http://ift.tt/2pVm4NG